Scope of Clinical Problem
Atherosclerosis is the leading cause of morbidity and mortality in the Western World.
Peripheral arterial occlusive disease (PAOD) due to atherosclerosis encompasses a spectrum of clinical syndromes with an incidence and prevalence nearly equal to coronary artery disease (18) . Approximately 15% of adults over the age of 55 have detectable hemodynamic impairments attributed to PAOD and the number of patients with PAOD can be expected to increase as the population ages (13, 42) . The two major clinical presentations of PAOD are intermittent claudication and critical limb ischemia (Table 1 ). In patients with intermittent claudication, arterial occlusive disease is manifested by insufficient blood flow during exercise. In patients with critical limb ischemia, blood flow is inadequate to meet the resting demands of the limb.
Even in its mildest form, and in the absence of "classic" symptoms of leg pain, PAOD is associated with marked disability and impairment in a patients' quality life (39) .
The primary pathophysiology of PAOD is impaired perfusion to the lower extremity.
Interestingly, the standard treatments for PAOD (antiplatelet agents, angiotensin-cascade antagonists, and cholesterol lowering therapy) are targeting general atherosclerotic risk-factor reduction but none are designed to improve tissue perfusion (24, 25, 48) . Life style modifications such as smoking cessation are clearly valuable in limiting limb loss in patients with critical limb ischemia. Exercise training is commonly regarded as the most effective therapy in patients with intermittent claudication but has been validated in small, selected patient populations with intense supervision (18) . Pharmacological therapies in PAOD are limited. Pentoxifylline, though widely prescribed in the United States, has little or no clinical benefit (46) . Cilostazol, a phosphodiesterase inhibitor, offers some clinical efficacy but its safety in patients with ventricular dysfunction remains in question and the FDA has issued a black box warning for patients with any degree of heart failure (4, 40) . Mechanical revascularization, either surgically or percutaneously, can be beneficial especially in patients with focal or "single-segment" atherosclerotic obstruction confined to aorto-iliac levels. Unfortunately, obstruction at multiple levels is common, and thus complete revascularization in patients with PAOD is unusual (23) .
Surgical therapy carries the risk of peri-operative morbidity and mortality, loss of conduit, and graft attrition. Percutaneous treatment is feasible in many patients with PAOD; however, intermediate-term (6-12 months) recurrent obstruction is common, especially in the large proportion of patients with diffuse or distal disease (20) .
New and more efficacious treatment options for PAOD are definitely needed. Numerous pre-clinical PAOD models exist and the purpose of this manuscript is to compare and contrast the various pre-clinical models of PAOD since the next generation of PAOD therapy will benefit from designing, describing, and validating approaches in pre-clinical PAOD models. "Preclinical" will be used to refer to any non-human in-vivo or in-vitro PAOD study with the exception of those studies performed exclusively to define the toxicity of an agent. Various models will be discussed in regards to their correlation to the human disease state ( Figure 1 ) and measures (i.e. endpoints) used to detect changes in perfusion that occur in response to therapy.
Establishing a Preclinical Model of PAOD
In the 1950's, Longland et al. (36) described an attempt at establishing a pre-clinical model of chronic ischemia with the injection of thrombin and a sclerosant into the femoral artery of rabbits. This model was associated with a high incidence of experimental animal loss but it did provide the conceptual framework for future chronic lower extremity ischemic models.
Since that time experimental hindlimb ischemia models have been developed in both small and large animals. In general, large animal models benefit from the ease of accurate identification of the lower extremity inflow vessels and their branches, as well as a multitude of blood flow measures that can be used throughout the course of the study. Small animal models benefit from the availability of transgenic lines (i.e. mice) and genetic tools for analyzing alterations in gene and protein expression.
Species to species variations in myocardial injury and blood flow recovery following coronary artery ligation have been recognized for many decades (28) . The same issue exists with lower extremity blood flow, where species to species variations, and genetic strains within the same species may be important. For example, Sunder-Plassman et al. (55) describe multiple lower extremity collateral pathways at baseline in the canine, necessitating the identification and occlusion of as many as 14 branches of the iliac, common femoral, and profunda femoris arteries in order to significantly alter flow. Likewise, Seifert et al. (53) describe an abundant collateral network at baseline in the rat, due to the physiologic absence of the profunda femoris artery. The limited baseline collateral network in the mouse, rabbit, and pig more closely resembles human vascular anatomy.
In addition to species and genetic background, it is important to consider the nature of the vascular injury. The tourniquet technique is a well-characterized and technically simple preclinical model that has been employed in cats, dogs, rats, rabbits, various species of primates, and even humans (2) . By placing an external tourniquet on the proximal part of the extremity and rapidly inflating to high pressure, prompt and virtual complete interruption of arterial and venous flow is achieved. If performed quickly, problems with venous engorgement are avoided.
However, the tourniquet method also occludes any potential collateral vessels and widespread muscle necrosis distal to the occlusion occurs after as little as six hours of ischemia, making this method unsuitable for studying chronic occlusive disease. Moreover, physiologic adaptations to the ischemic insult are limited by the complete isolation of the limb from the systemic circulation. This model may involve direct compression and injury to myocytes, as well as peripheral nerves. Therefore, this approach is more suited for studying acute ischemia and reperfusion injury that occurs with the re-establishment of flow after acute arterial occlusion.
Surgical ligation of the lower extremity inflow vessels, although still a form of acute injury, has also been employed in an attempt to create states of chronic impaired flow. Vessel location, degree of side branch and collateral vessel occlusion, and species variability all contribute to the degree of ischemia seen following ligation (Figures 1 and 2 ). Occlusions closer to the aorta (e.g. common iliac artery) and occlusions performed with the ligation of potential collateral sources produce more profound effects than simple distal occlusions (e.g. common femoral). Ligations alone, however, often do not result in a significant or sustainable reduction in resting blood flow. Lower extremity blood flow remains unchanged at rest following simple femoral artery (8) In humans, PAOD is largely a bilateral disease (23, 24) . Models of bilateral common iliac artery ligation and simultaneous arterial and venous ligation have also been evaluated. Cheboun et al. (9) report gangrene in one or both legs in 4/7 rats and 3 deaths within the first week following bilateral common iliac artery ligation. In addition to creating an acute insult that is too extensive to permit evaluation of chronic ischemia, this model prohibits using the contra-lateral extremity as a control. Similarly, simultaneous ligation of the iliac artery and vein on one side resulted in all rats exhibiting gangrene (4/7 rats died in 4-6 days) and tissue loss of at least the foot (9) . It is likely that the added venous insufficiency exacerbated tissue ischemia in this model (32) . In general, in contrast to unilateral arterial ligations, bilateral arterial ligation models, especially if associated with venous ligation, have a substantial morbidity and mortality following the acute insult.
Current Pre-Clinical Models of Chronic Hindlimb Ischemia
In 1992, Pu et al. (45) described a pre-clinical hindlimb ischemia model that did produce persistent ischemia at rest. As opposed to prior ligation models, their model incorporated complete excision of the lower extremity inflow arteries, markedly reducing the possibility of any recanalization or short bridging-collateral formation. The technique was initially applied in New Zealand white rabbits and the distal external iliac artery (just above the level of the inguinal ligament), inferior epigastric, profunda femoral, circumflex femoral, and superior epigastric arteries were ligated proximally, while the popliteal and saphenous arteries were ligated distally ( Figure 2 ). The entire femoral artery was then excised from just above the inguinal ligament to the level of the proximal popliteal and saphenous arteries. As a consequence, blood flow to the ischemic limb became completely dependent upon collaterals issuing from the internal iliac artery ( Figure 2 ). Clinically, all animals had noticeable limping of their ischemic hindlimb on post-operative day 1. After day 10, the majority had either mild hindlimb limping or a functionally normal leg but noticeable muscular atrophy. Some animals developed superficial tissue necrosis in the foot, a few had a nonfunctional hindlimb, and six died before study termination with no deaths attributable to the ischemia-inducing procedure. Angiograms showed slow filling of the arterial tree beyond the excised femoral artery with few thigh collaterals that persisted through 90 days. Assessments performed pre-operatively and on post-operative days 1, 10, 20, 30, 40, and 90 days demonstrated an impaired arterial perfusion as assessed by calf blood pressure ratio and calf radioisotopic perfusion scanning, as well as increased femoral venous lactate levels, that was persistent throughout the study period (Table 2) . Qualitatively similar results have been described in the same rabbit model by other investigators (26).
In the previously described models, arterial ligation is followed by an endogenous response that limits the extent of the ischemia in the distal tissue. There is a large range in the endogenous angiogenic/arteriogenic response in humans. Children following Blalock-Taussig operations and adults with coarctation or aplasia of large vessels develop a significant collateral vasculature (31, 51, 59 ) and this shows that humans, given an appropriate stimulus and a healthy vascular bed, can mount an angiogenic response that can prevent ischemia. However, a number of demographic and clinical predictors, highlighted in Table 3 , can clearly impair this response (22, 58) . In order to be able to integrate many of the items found in Table 3 (50) , hypercholesterolemic (12, 15, 56) , hyperhomocysteinemic (16) , and aged (49) mice. For example (Figure 3 ), femoral artery ligation and excision in nonobese diabetic mice (NOD), which develop a form of diabetes with clinical features similar to the human type-1 diabetes mellitus, results in an LDPI ratio of 0.5 at 35 days and the same procedure in APO E -/-mice results in a LDPI ratio of 0.6 at 35 days (50,12).
As described in Table 1 , patients with PAOD have two major and distinct clinical manifestations. Patients with intermittent claudication have normal or slightly diminished lower extremity blood flow at rest but an inability to adequately increase blood flow with exercise (23, 24) . Therefore, the arterial ligation model or the ligation with limited excision model, with an intact capacity to produce an angiogenic/arteriogenic response, will exhibit near normal flows at rest but an impaired limb blood flow capacity with stress (e.g. exercise), and thus is well suited to study intermittent claudication in PAOD (60) (61) (62) (63) (64) . The ligation and excision method, especially if performed in the background of an impaired angiogenic/arteriogenic response, will result in reductions in blood flow to the ischemic limb even at rest, and would therefore more closely replicate the clinical situation of patients with critical limb ischemia.
Endpoints for Assessing Changes in Perfusion in Hindlimb Ischemia Models
A major therapeutic goal in PAOD is to increase perfusion and pre-clinical models can be used to assess the potential utility of therapeutic modalities that might augment perfusion to the ischemic limb. In the use of pre-clinical models the timing of the perfusion assessments is critical. Since all models are associated with some degree of perfusion recovery, interventions or agents tested at the time of surgery, or shortly after, will be measuring the capacity of an agent to improve upon the degree of recovery. At later time points following surgery (typically more than one week) the models are stable and there will be far less in the degree of catch up of the ischemic limb to the non-ischemic limb. The down-side is that at later time points perfusion in the ischemic limb will be closer to perfusion in the non-ischemic limb and thus the ability to detect the "efficacy" of an intervention or agent may be less. Studies to date have utilized a variety of techniques to evaluate changes in perfusion, and a standardized protocol needs to be established to enable comparison among studies and identification of therapies that warrant clinical trials.
Histologic Measurements of Angiogenesis
In pre-clinical models, the assessments of changes in perfusion made on a histologic level are by themselves not valuable. The correlation of the histological measures to human disease is also uncertain. For example, in humans, in the absence of pathologic disease states, capillary density is directionally correlated with the oxidative capacity and endurance of a muscle group (27) . Interestingly, although patients with PAOD (i.e. intermittent claudication) have normal or near normal resting lower extremity blood flow, they exhibit skeletal muscle abnormalities compared to healthy controls (6) . Paradoxically, despite having a reduced aerobic capacity, the skeletal muscle capillary density appears to be increased in patients with PAOD and the relative increase in vascular density appears to be proportional to the extent of skeletal muscle hypoxia (6, 23) . This could be viewed as a potentially beneficial adaptation and as an attempt to compensate for the reductions in blood flow Capillary density remains the most commonly assessed histologic measure of perfusion in pre-clinical models. Endothelial cells are quantified using immunohistochemical techniques, and the capillary density of ischemic tissue and contralateral normal tissue are compared (10) .
Since muscle atrophy is a common phenomenon in the hindlimb ischemia models, determination of the number of "muscle fiber capillary contacts" rather than the number of "capillaries/mm 2 " may be more accurate as the former is less influenced by changes in muscle fiber size.
Regardless of the assessment used, a context for the interpretation of the findings is unclear.
Additional tissue assessments that may prove valuable include changes in muscle fiber type, fibrosis, and evidence of the extent of cell death and proliferation (14) .
Measurements of Lower Extremity Blood Flow
Calf Finally, flow probes may be implanted over major inflow vessels (e.g., common iliac artery, internal iliac artery) to the ischemic limb and flow changes in response to vasodilator administration (e.g. adenosine or papaverine) can be readily determined (3,7) . Unfortunately, the sites where blood flow is measured for this purpose is also a source for blood supply to regions other than the collateral-dependent tissue of the distal hindlimb. Thus, when a vasodilator is administered, blood flow markedly increases to these regions, since vascular resistance of normal tissue can decrease far more than the resistance of the collateral circuit. As a result, the measurement of blood flow only partially represents flow delivered to the collateral-dependent
tissue. This establishes a potential to mistakenly attribute changes in flow to possible adaptations in the collateral circuit introduced by an arteriogenic treatment.
Direct Measures of Perfusion to Ischemic Tissue
The best means of assessing perfusion to the ischemic limb is to measure the capacity for collateral-dependent blood flow. This can be achieved when, a) blood flow that is delivered to the collateral-dependent tissue is measured, and b) when the resistance of the collateral circuit is the dominant resistance determining blood flow. The first condition is most easily achieved by measuring blood flow to the distal hindlimb (e.g., calf muscles) with the use of microspheres.
Regional blood flow is proportional to the number of microspheres trapped in the area of interest.
A determination of tissue blood flow is made using the following equation: sample flow ml/min ÷ radioactivity in reference sample = tissue flow ÷ radioactivity in organ. Achieving the latter condition is more challenging. Simple vasodilator administration can be problematic, since isolated administration of vasodilator therapy to the collateral-dependent tissue is difficult and systemic effects of a reduced blood pressure can confound an experiment. In a similar manner, anesthesia, if associated with excessive hypotension, can alter these measures of perfusion. It is possible to circumvent this problem by using muscle contractions during exercise in-vivo (62) or in-situ (57, 63) . Muscle contractions impart the most powerful stimulus for vasodilatation. As a result, vascular resistance of the collateral circuit is dominant and blood flow to the calf muscles is collateral-dependent (61) . Because of the rigorous nature of the measurement conditions, this assessment of collateral blood flow has been thus far relegated to experimental studies.
Anatomic Measures of Blood Flow:
Although contrast angiography is sometimes used to visualize collateral vessels, the complexity of the collaterals, the multiple potential sources of the collaterals, and the lack of sufficient radiographic spatial resolution limits its ability to accurately measure collateral blood flow. Angiographic data, when present, is valuable mainly as a correlate to other measures such as calf blood flow, even when detailed analysis systems are used. Magnetic resonance imaging (MRI) is a rapidly advancing approach for regional blood flow assessments, as well as assessments of blood vessel function/integrity. MR imaging provides a number of data points to attempt to understand and quantitatively measure lower extremity perfusion. Buschmann et al.
(7) used MRI to visualize the femoral artery in multiple cross-sectional views and when perpendicular to the direction of flow was able to obtain assessments of collateral dependent flow in a manner similar to the microsphere method described above. Contrast-enhanced MR, with first pass gadolinium-based contrast agent, can be used to visualize arteries (MRA) and obtain regional and muscle specific perfusion measures.
Considerations for Pre-Clinical to Clinical Application in Trials of Angiogenesis
Pre-clinical hindlimb ischemia models have been used extensively to investigate potential therapeutic angiogenic agents. Angiogenesis is the growth and proliferation of blood vessels from existing vascular structures while therapeutic angiogenesis seeks to employ this phenomena as a method to increase perfusion to ischemic tissue (29) . Over the past two decades a large number of cytokine growth factors that stimulate endothelial cell proliferation in-vitro and, either directly or indirectly, induce angiogenesis ex-vivo, or modulate angiogenesis in-vivo, have been identified (17) . The vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) families have been the most frequently studied, and these factors may be the most potent. 
Limitations of Using Animal Studies to Predict Outcomes in Humans
Both bFGF (63, 1) and VEGF121 (37, 19) This is perhaps the best way to assess changes in perfusion to the ischemic limb, but has seldom been employed due to the complexities involved. Instead, total perfusion to the ischemic limb is often used which may lead to false estimates of efficacy.
Future Pre-clinical and Clinical Trials
Despite their limitations, preclinical studies have the potential to provide a great deal of data to aid clinical development and may provide information that is useful beyond the simple answer of "did the agent show efficacy or no efficacy". For example, groups have been able to optimize dosing regimens (e.g., site, nature of delivery, duration) that could be critical to better develop the tissue environment more conducive to arteriogenesis (2, 34) . Pre-clinical models also offer the unique opportunity to explore the feasibility of combination therapy that is often difficult to employ in clinical trials, such as the effects of administering multiple angiogenic growth factors or combining angiogenic therapy with exercise (38, 64 In summary, PAOD covers a spectrum of disorders that are the result of impaired perfusion usually to the lower extremity. PAOD is a disease in need of new therapeutic treatment modalities. Therapeutic angiogenesis is an investigational approach designed to improve tissue perfusion and currently the field of therapeutic angiogenesis remains in its infancy with successes being reported in some instances and disappointments in others. If the field is to advance, scientifically rigorous translational studies carried out in appropriate animal models will be necessary to develop and assess potential pro-angiogenic therapies prior to their use in humans. Consequently, we hope the information contained in this review will help investigators make informed decisions regarding the planning of future studies such that these therapies may one day find their way into every day clinical practice. Goal of therapy ↑PWT, ↑QOL Limb salvage, mortality reduction PWT = peak walking time on treadmill exercise protocol QOL = quality of life as assessed by validated questionnaires 
